CA2876909C - Itraconazole compositions and dosage forms, and methods of using the same - Google Patents
Itraconazole compositions and dosage forms, and methods of using the same Download PDFInfo
- Publication number
- CA2876909C CA2876909C CA2876909A CA2876909A CA2876909C CA 2876909 C CA2876909 C CA 2876909C CA 2876909 A CA2876909 A CA 2876909A CA 2876909 A CA2876909 A CA 2876909A CA 2876909 C CA2876909 C CA 2876909C
- Authority
- CA
- Canada
- Prior art keywords
- itraconazole
- composition
- dose
- lozanoc
- conditions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012902624 | 2012-06-21 | ||
| AU2012902624A AU2012902624A0 (en) | 2012-06-21 | Itraconazole formulations and uses | |
| PCT/US2013/047135 WO2013192566A1 (en) | 2012-06-21 | 2013-06-21 | Itraconazole compositions and dosage forms, and methods of using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2876909A1 CA2876909A1 (en) | 2013-12-27 |
| CA2876909C true CA2876909C (en) | 2022-08-16 |
Family
ID=49769445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2876909A Active CA2876909C (en) | 2012-06-21 | 2013-06-21 | Itraconazole compositions and dosage forms, and methods of using the same |
Country Status (11)
| Country | Link |
|---|---|
| US (7) | US8921374B2 (https=) |
| EP (1) | EP2863911A4 (https=) |
| JP (2) | JP2015531749A (https=) |
| KR (3) | KR20200065093A (https=) |
| CN (2) | CN109674795A (https=) |
| AU (3) | AU2013278001A1 (https=) |
| BR (1) | BR112014031706A8 (https=) |
| CA (1) | CA2876909C (https=) |
| HK (1) | HK1207288A1 (https=) |
| MX (1) | MX366829B (https=) |
| WO (1) | WO2013192566A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200065093A (ko) | 2012-06-21 | 2020-06-08 | 메인 파마 인터내셔널 프로프라이어터리 리미티드 | 이트라코나졸 조성물 및 투여형, 그리고 이것들의 사용 방법 |
| US9192609B2 (en) | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
| CA3073228A1 (en) | 2017-08-20 | 2019-02-28 | University Of Connecticut | Azole analogues and methods of use thereof |
| US20190365743A1 (en) * | 2018-05-30 | 2019-12-05 | Hedgepath Pharmaceuticals, Inc. | Hedgehog pathway inhibition for treatment of high-risk basal cell carcinoma or high-risk basal cell carcinoma nevus syndrome |
| US12435067B2 (en) | 2019-08-09 | 2025-10-07 | University Of Connecticut | Truncated itraconazole analogues and methods of use thereof |
| US20210346506A1 (en) | 2020-05-07 | 2021-11-11 | Guibai Liang | Prodrug of itraconazole and uses thereof |
| WO2023007514A1 (en) * | 2021-07-29 | 2023-02-02 | Dr. Reddy's Laboratories Limited | Improved oral bioavailable pharmaceutical compositions |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3110794B2 (ja) | 1991-06-05 | 2000-11-20 | ユーシービージャパン株式会社 | １，４−ジヒドロピリジン誘導体を含有する製剤 |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| PH30929A (en) | 1992-09-03 | 1997-12-23 | Janssen Pharmaceutica Nv | Beads having a core coated with an antifungal and a polymer. |
| DE69628276T2 (de) | 1995-07-26 | 2004-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Zubereitung von xanthinderivaten als feste dispersion |
| WO1997044014A1 (en) | 1996-05-20 | 1997-11-27 | Janssen Pharmaceutica N.V. | Antifungal compositions with improved bioavailability |
| ATE273002T1 (de) | 1996-06-28 | 2004-08-15 | Schering Corp | Feste lösung eines fungizids mit erhöhter bioverfügbarkeit |
| PT1039909E (pt) | 1997-12-31 | 2003-02-28 | Choongwae Pharma Corp | Metodo de producao e composicao de uma preparacao oral de itraconazole |
| KR100336090B1 (ko) | 1998-06-27 | 2002-05-27 | 윤승원 | 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제 |
| WO2000040220A1 (en) | 1999-01-06 | 2000-07-13 | Korea Research Institute Of Chemical Technology | Method of preparing pharmaceutical active ingredient comprising water-insoluble drug and pharmaceutical composition for oral administration comprising the same |
| ATE400252T1 (de) | 1999-02-10 | 2008-07-15 | Pfizer Prod Inc | Pharmazeutische feste dispersionen |
| EP1239831B1 (en) * | 1999-12-23 | 2012-10-31 | Mayne Pharma International Pty Ltd. | Improved pharmaceutical compositions for poorly soluble drugs |
| KR100425755B1 (ko) * | 2001-08-27 | 2004-04-03 | 주식회사 원진신약 | 이트라코나졸을 함유하는 조성물 및 그 제조방법 |
| KR100529766B1 (ko) | 2003-09-09 | 2005-11-17 | 한미약품 주식회사 | 음식물 섭취에 따른 영향이 적은, 이트라코나졸경구투여용 조성물 및 이의 제조 방법 |
| US20050058670A1 (en) | 2003-09-09 | 2005-03-17 | Jong-Soo Woo | Oral itraconazole composition which is not affected by ingested food and process for preparing same |
| JP4342426B2 (ja) * | 2004-11-24 | 2009-10-14 | 科研製薬株式会社 | イトラコナゾール経口投与用製剤 |
| JP5538718B2 (ja) * | 2005-08-08 | 2014-07-02 | アボット ゲーエムベーハー ウント コンパニー カーゲー | 改善された生物学的利用能をもつイトラコナゾール組成物 |
| BRPI0713533A2 (pt) * | 2006-06-26 | 2012-04-17 | Mutual Pharmaceutical Co | formulações de agente ativo, métodos de fabricação, e métodos de uso |
| WO2008124132A1 (en) * | 2007-04-05 | 2008-10-16 | The Johns Hopkins University | Chirally pure isomers of itraconazole and inhibitors of lanosterol 14a- demethylase for use as angiogenesis inhibitors |
| KR20200065093A (ko) | 2012-06-21 | 2020-06-08 | 메인 파마 인터내셔널 프로프라이어터리 리미티드 | 이트라코나졸 조성물 및 투여형, 그리고 이것들의 사용 방법 |
-
2013
- 2013-06-21 KR KR1020207015341A patent/KR20200065093A/ko not_active Ceased
- 2013-06-21 HK HK15107854.3A patent/HK1207288A1/xx unknown
- 2013-06-21 CN CN201811419638.3A patent/CN109674795A/zh active Pending
- 2013-06-21 CN CN201380040270.9A patent/CN104507480A/zh active Pending
- 2013-06-21 EP EP13806558.6A patent/EP2863911A4/en active Pending
- 2013-06-21 JP JP2015518624A patent/JP2015531749A/ja active Pending
- 2013-06-21 AU AU2013278001A patent/AU2013278001A1/en not_active Abandoned
- 2013-06-21 BR BR112014031706A patent/BR112014031706A8/pt active Search and Examination
- 2013-06-21 US US13/924,222 patent/US8921374B2/en active Active
- 2013-06-21 CA CA2876909A patent/CA2876909C/en active Active
- 2013-06-21 KR KR20157001531A patent/KR20150043296A/ko not_active Ceased
- 2013-06-21 MX MX2015000179A patent/MX366829B/es active IP Right Grant
- 2013-06-21 KR KR1020217010610A patent/KR20210043721A/ko not_active Abandoned
- 2013-06-21 WO PCT/US2013/047135 patent/WO2013192566A1/en not_active Ceased
-
2014
- 2014-10-10 US US14/511,420 patent/US9272046B2/en active Active
-
2015
- 2015-10-14 US US14/882,662 patent/US9713642B2/en active Active
-
2017
- 2017-06-15 US US15/623,742 patent/US20170348421A1/en not_active Abandoned
-
2018
- 2018-02-22 AU AU2018201298A patent/AU2018201298B2/en active Active
- 2018-07-02 JP JP2018126027A patent/JP6757367B2/ja active Active
- 2018-11-21 US US16/198,645 patent/US10463740B2/en active Active
-
2019
- 2019-11-01 US US16/671,606 patent/US10806792B2/en active Active
-
2020
- 2020-08-14 AU AU2020217438A patent/AU2020217438A1/en not_active Abandoned
- 2020-10-19 US US17/074,497 patent/US11638758B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11638758B2 (en) | Itraconazole compositions and dosage forms, and methods of using the same | |
| US20110319384A1 (en) | Pharmaceutical Compositions | |
| US20160101105A1 (en) | High drug load tablet | |
| TW200948358A (en) | Dissolution improved pharmaceutical composition comprising olmesartan medoxomil | |
| ES3055121T3 (en) | Formulations of ag10 | |
| BR112018011085B1 (pt) | Composição farmacêutica compreendendo doravirina, fumarato de tenofovir desoproxila e lamivudina e processo para sua preparação | |
| ES2963886T3 (es) | Comprimidos que contienen tamsulosina y solifenacina | |
| CN119546312A (zh) | 用于治疗银屑病的包含a3腺苷受体激动剂的药物组合物 | |
| US20250312342A1 (en) | Methods of treating disorders with phthalazinone derivatives | |
| EP4531816B1 (en) | PHARMACEUTICAL FORMULATIONS OF BICTEGRAVIR AND LENACAPAVIR | |
| US20260124146A1 (en) | Modified release tolcapone formulations | |
| WO2026006909A1 (en) | Method for improving cognition in alzheimer's disease patient | |
| WO2023007514A1 (en) | Improved oral bioavailable pharmaceutical compositions | |
| EP4601624A2 (en) | Modified release tolcapone formulations | |
| HK40056307B (en) | Formulations of ag10 | |
| HK40056307A (en) | Formulations of ag10 | |
| US20250228784A1 (en) | Antifibrotic composition | |
| WO2021234430A1 (en) | Modified release dosage form comprising vildagliptin and process for manufacturing the same | |
| US20060099267A1 (en) | High-dosage extended-release formulation of gepirone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180613 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250613 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250613 |